| Literature DB >> 30209326 |
Mar Marcos-López1,2, Josep A Calduch-Giner3, Luca Mirimin4, Eugene MacCarthy4, Hamish D Rodger5, Ian O'Connor4, Ariadna Sitjà-Bobadilla6, Jaume Pérez-Sánchez3, M Carla Piazzon7.
Abstract
Amoebic gill disease (AGD) is one of the main diseases affecting Atlantic salmon (Salmo salar L.) mariculture. Hallmarks of AGD are hyperplasia of the lamellar epithelium and increased production of gill mucus. This study investigated the expression of genes involved in mucus secretion, cell cycle regulation, immunity and oxidative stress in gills using a targeted 21-gene PCR array. Gill samples were obtained from experimental and natural Neoparamoeba perurans infections, and sampling points included progressive infection stages and post-freshwater treatment. Up-regulation of genes related to mucin secretion and cell proliferation, and down-regulation of pro-inflammatory and pro-apoptotic genes were associated with AGD severity, while partial restoration of the gill homeostasis was detected post-treatment. Mucins and Th2 cytokines accoun ted for most of the variability observed between groups highlighting their key role in AGD. Two mucins (muc5, muc18) showed differential regulation upon disease. Substantial up-regulation of the secreted muc5 was detected in clinical AGD, and the membrane bound muc18 showed an opposite pattern. Th2 cytokines, il4/13a and il4/13b2, were significantly up-regulated from 2 days post-infection onwards, and changes were lesion-specific. Despite the differences between experimental and natural infections, both yielded comparable results that underline the importance of the studied genes in the respiratory organs of fish, and during AGD progression.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30209326 PMCID: PMC6135806 DOI: 10.1038/s41598-018-32019-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic representation of the two different trials (in vivo challenge with Neoparamoeba perurans and field sampling) used in this study. SD = initial stocking density. Black dots represent the sequential sampling points (dpi = days post-infection; dpt = days post-transfer). Blue arrows in the field sampling section show initial sea transfer and posterior freshwater treatment. Details on type of lethal samples taken are described in the material and methods section.
Figure 2(A) Cultured Neoparamoeba perurans in marine malt yeast agar plates covered with filtered and sterile seawater (x400). (B) Macroscopic AGD lesions in experimentally infected fish sampled at 21 dpi. Note mucoid patches at base of filaments (yellow circles).
Figure 3Histopathology assessment of AGD infection (H&E staining). (A) Sample from negative control fish at 2 dpi showing non-infected gills with normal lamellar structure. Scale bar = 300 μm. (B) Sample from infected fish at 2 dpi showing infection signs such as mild focal hyperplasia and fusion of lamellar epithelium (*). Scale bar = 200 μm. (C) Sample from GS 2 fish (field sampling) showing moderate multifocal hyperplasia and fusion of lamellar epithelium (*) with associated presence of amoeboid organisms (arrow heads). Scale bar = 200 μm. (D) Histology sample taken 4 days after freshwater treatment with less prominent hyperplastic foci. Note regression of inter-lamellar cell mass (arrows). Scale bar = 200 μm.
List of selected genes and forward and reverse primers for real-time qPCR.
| Pathway | Gene name (Symbol) | Accession number | Sequence (5′-3′) |
|---|---|---|---|
| Housekeeping |
| AF012125 | (F):CCATCCAGGCAGTGTTGT; (R):CGGAGTCCATGACGATACC |
| Mucins |
| XM_014213637 | (F):AAGAGCAGCGAGGTGGTG; (R):TCCGTTGACTTGGCAGATGA |
|
| JT819124 | (F):CCGTGCTGGGAGACATTATGAAGT; (R):TGCTGGAGAGGGAAAGGGTAAC | |
|
| XM_014183074 | (F):CGACTGCCACAAAGCCATTAGG; (R):GCGTGTTGCTGCGTGTCTT | |
| Immune genes |
| NM_001123617 | (F):GTGTATGTGGGAGCAGTGTT; (R):GAAGCCTGTTCTCTGTGACT |
|
| AB574339 | (F):GCATCGTTGTGAAGAGCCAAGA; (R):GAAGTCTCCTCAGCTCCACCT | |
|
| HG794525 | (F):GTGAAGGAGAACGGTGATGAGGAACAGC; (R):GGCACAGTTGAAGAGGTTTGTCAGGAGAT | |
|
| XM_014129261 | (F):GCCATCCGTGGACAGATACT; (R):TCTCCCTCCTGGTCAATCTCT | |
| MAPK pathways |
| EF123660, EF123661 | (F):ACGGGTCTGAAGATCGCTGTGAA; (R):TCTGTAGGTTCTCTTGGCGTGGAT |
|
| XM_014176343 | (F):CACAGCACTCTGGACACT; (R):ACCTCCTCCTCGTCAGTT | |
|
| XM_014158394 | (F):GCGGCTGTCCTATCTGCTCTAC; (R):CGGCGTGAAGGTGCTTGATG | |
| Oxidative and cellular stress |
| NM_001139807 | (F):GAGGGACGAGGATGGGAAG; (R):ATCGGTGGTCTGCTGGAG |
|
| NM_001141684 | (F):CCTGCCTACTTCAACGATTCACAGAGACA; (R):CCAGCGATCACTCCAGCGTCCTTA | |
| Cell proliferation |
| NM_001140130 | (F):GGAGAGGACTACGACGAGAGG; (R):CCACCACGGACTTGAGGAC |
|
| NM_001146606 | (F):CTGCTAACACCGACTGGCTGAAC; (R):CTCCACGACCTTGCCGAACAC | |
|
| BT056931 | (F):GCCGTGACCTGTCTCAGATTG, (R):CCGAGAACTTAACGCCATCCTT | |
|
| XM_014191766 | (F):GACACCAAGTTCTACCAGAGCCTAATCAGT; (R):GCGTCCACAGCGTCCTCCAT | |
| Apoptosis |
| BT058777 | (F):CATCATCACCCTGGAGACA; (R):CACACACGCACCTCAAAG |
| Transcription Factors |
| NM_001142713 | (F):GCATACGGCAGCAGCAACTT; (R):GCTCGGCTACCAGACTGTGT |
|
| BT043977 | (F):CGCTCTCCTCCTTGTGTATGA; (R):TGTGGATGGCAGTGGTAGA | |
|
| BT059519 | (F):GGTTGTGGCTGGAAGTTC; (R):CAGTGTGCTTACGGAAATGG | |
| Inflammation |
| NM_001139832 | (F):ATCCACCAGACAGTCACACACCTTC; (R):GCCACTCCAAACACCTCCGAGAC |
Figure 4Phylogenetic tree of protein sequences for Muc5, Muc2 and Muc18, including the Atlantic salmon sequences used in the present study. GenBank accession numbers are provided for each sequence.
Figure 5PCA analysis for the in vivo challenge samples representing the distribution of infected samples at 2, 7, 14 and 21 dpi. Analysis was based on fold-changes of all genes for each individual sample (smaller symbols) relative to the negative control at each time point. The ellipses indicate the group dispersion/variability from the centroid (larger symbols) calculated using all individual fold-changes values/group.
Figure 6(A) PCA analysis for the field samples representing the distribution of lesion samples of GS 1, GS 2 and treated groups. Analysis was based on fold-changes of all genes for each individual sample (smaller symbols) relative to GS 0. The ellipses indicate the group dispersion/variability from the centroid (larger symbols) calculated using all individual fold-changes values. (B) PCA analysis for the field samples representing the distribution of lesion and non-lesion samples of GS 1, GS 2 and treated groups. Analysis is based on fold-changes of all genes for each individual sample relative to GS 0. For clarity, individual values were omitted from the plot and only the group centroids were plotted.
Field experiment gill score values predicted using partial least squares regression.
| Group | GS 0 | GS 1 Lesion | GS 1 Non-lesion | GS 2 Lesion | GS 2 Non-lesion | Treated Lesion | Treated Non-lesion |
|---|---|---|---|---|---|---|---|
| Predicted GS | 0.14 ± 0.078 | 1.03 ± 0.419 | −0.01 ± 0.089 | 2.09 ± 0.519 | 0.03 ± 0.102 | −0.19 ± 0.029 | 0.05 ± 0.061 |
The model was constructed using the expression values of the genes that contributed most to the variability observed in components 1 and 2 of the PCA analyses shown in Figs 5 and 6 (muc5, muc18, muc2, il4/13a, il4/13b2 and tnfα3) as X variables, and gill score (GS) as Y variable. The in vivo challenge dataset served as the training set. Values show the mean (±SEM) predicted GS of the different field experiment sample groups.
Figure 7Relative expression of genes showing statistically significant changes (+p < 0.1, *p < 0.05, **p < 0.01) in the in vivo challenge experiment. Mucins and cytokines are represented in (A), and the other differentially expressed genes are shown in (B). Fold changes (FC) were calculated as the relative expression in the infected (positive) versus the non-infected (negative) samples. Genes showing FC > 1 were up-regulated in infected samples, whereas genes with FC < 1 were down-regulated in infected samples.
Figure 8Relative expression of genes showing statistically significant changes (+p < 0.1, *p < 0.05, **p < 0.01) in the field samples. Mucin and cytokines are represented in (A), and the other differentially expressed genes are shown in (B). Fold changes (FC) were calculated as the relative expression in lesion (L) versus non-lesion (NL) areas for GS 1 and GS 2, and in lesion areas post-treatment (TX-L) versus lesion areas at GS 2. Genes showing FC > 1 were up-regulated in lesion areas or post-treatment, whereas genes with FC < 1 were down-regulated in lesion areas or post-treatment.